Representative chromatograms.

<p>A) Blank human plasma, B) Efavirenz in human plasma at Lowest limit of quantification (LLOQ, 1.0 ng/mL) and C) ¹³C₆-Efavirenz (Internal standard, 10 ng/mL) in human plasma.</p

HPLC-MS method for the quantification of nine anti-HIV drugs from dry plasma spot on glass filter and their long term stability in different conditions.

<p>Accuracy and precision for Efavirenz Calibration standards in human plasma.</p

Summary of Validation outcomes of Efavirenz in human plasma.

<p>Summary of Validation outcomes of Efavirenz in human plasma.</p

Summary of stability outcomes of Efavirenz in human plasma.

<p>Summary of stability outcomes of Efavirenz in human plasma.</p

Discovery of Dabrafenib: A Selective Inhibitor of Raf Kinases with Antitumor Activity against B‑Raf-Driven Tumors

Hyperactive signaling of the MAP kinase pathway resulting from the constitutively active B-Raf^V600E mutated enzyme has been observed in a number of human tumors, including melanomas. Herein we report the discovery and biological evaluation of GSK2118436, a selective inhibitor of Raf kinases with potent in vitro activity in oncogenic B-Raf-driven melanoma and colorectal carcinoma cells and robust in vivo antitumor and pharmacodynamic activity in mouse models of B-Raf^V600E human melanoma. GSK2118436 was identified as a development candidate, and early clinical results have shown significant activity in patients with B-Raf mutant melanoma